Kristine Griffett

Dr. Kristine Griffett

Auburn University, Auburn, Alabama, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
TBThomas P. Burris
Thomas P. Burris
LSLaura A. Solt
Laura A. Solt
YWYongjun Wang
Yongjun Wang
CCChristine Crumbley
Christine Crumbley
SBSubhashis Banerjee
Subhashis Banerjee
DKDouglas J. Kojetin
Douglas J. Kojetin
Nuclear receptors are ligand-activated transcription factors and include the receptors for steroid hormones, lipophilic vitamins, sterols, and bile acids. These receptors serve as targets for development of myriad drugs that target a range of disorders. Classically defined ligands that bind to the ligand-binding domain of nuclear receptors, whether they are endogenous or synthetic, either activate receptor activity (agonists) or block activation (antagonists) and due to the ability to alter activity of the receptors are often termed receptor “modulators.” The complex pharmacology of nuclear receptors has provided a class of ligands distinct from these simple modulators where ligands display agonist/partial agonist/antagonist function in a tissue or gene selective manner. This class of ligands is defined as selective modulators. Here, we review the development and pharmacology of a range of selective nuclear receptor modulators.

1 July 2015 in Cancer Cell
Verified
Journal Article
Closed access
CFColin A. Flaveny
Colin A. Flaveny
KGKristine Griffett
Kristine Griffett
Bahaa ElgendyBahaa Elgendy
Bahaa Elgendy
MKMelissa Kazantzis
Melissa Kazantzis
MSMonideepa Sengupta
Monideepa Sengupta
TBThomas P. Burris
Thomas P. Burris

23 December 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSubhashis Banerjee
Subhashis Banerjee
YWYongjun Wang
Yongjun Wang
LSLaura A. Solt
Laura A. Solt
KGKristine Griffett
Kristine Griffett
MKMelissa Kazantzis
Melissa Kazantzis
TBThomas P. Burris
Thomas P. Burris
Synthetic drug-like molecules that directly modulate the activity of key clock proteins offer the potential to directly modulate the endogenous circadian rhythm and treat diseases associated with clock dysfunction. Here we demonstrate that synthetic ligands targeting a key component of the mammalian clock, the nuclear receptors REV-ERBα and β, regulate sleep architecture and emotional behaviour in mice. REV-ERB agonists induce wakefulness and reduce REM and slow-wave sleep. Interestingly, REV-ERB agonists also reduce anxiety-like behaviour. These data are consistent with increased anxiety-like behaviour of REV-ERBβ-null mice, in which REV-ERB agonists have no effect. These results indicate that pharmacological targeting of REV-ERB may lead to the development of novel therapeutics to treat sleep disorders and anxiety.

27 December 2012 in ACS Chemical Biology
Verified
Journal Article
Closed access
KGKristine Griffett
Kristine Griffett
LSLaura A. Solt
Laura A. Solt
Bahaa ElgendyBahaa Elgendy
Bahaa Elgendy
TKTheodore M. Kamenecka
Theodore M. Kamenecka
TBThomas P. Burris
Thomas P. Burris

1 April 2015 in Molecular Metabolism
Verified
Journal Article
Open access
KGKristine Griffett
Kristine Griffett
RWRyan D. Welch
Ryan D. Welch
CFColin A. Flaveny
Colin A. Flaveny
GKGrant R. Kolar
Grant R. Kolar
BNBrent A. Neuschwander-Tetri
Brent A. Neuschwander-Tetri
TBThomas P. Burris
Thomas P. Burris
Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepatic steatosis. We hypothesized that suppression of lipogenesis, which is pathologically elevated in NASH may suppress progression of hepatic steatosis to NASH. NASH was induced in B6 V-lep (ob)/J (ob/ob) mice using a custom complete rodent diet (HTF) containing high amounts of trans-fat, fructose, and cholesterol. Once NASH was induced, mice were treated with SR9238 for one month by i.p. injection. Plasma lipid levels and liver health were analyzed by clinical chemistry. QPCR, western blot, and immunohistochemistry were used to assess disease severity. Ob/ob mice are obese and diabetic thus they are commonly used as models for the study of metabolic diseases. These mice quickly developed the NASH phenotype when provided the HTF diet. The mice develop hepatic steatosis, severe hepatic inflammation and fibrosis on the HTF diet. Treatment with SR9238 significantly reduced the severity of hepatic steatosis and most importantly reduced hepatic inflammation and ameliorated hepatic fibrosis. Here, we demonstrate that an LXR inverse agonist, SR9238, is effective in reduction of hepatic steatosis, inflammation and fibrosis in an animal model of NASH. These results have important implications for the development of therapeutics for treatment NASH in humans.

1 October 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KGKristine Griffett
Kristine Griffett
TBThomas P. Burris
Thomas P. Burris